Details for Patent: 11,666,573
✉ Email this page to a colleague
Which drugs does patent 11,666,573 protect, and when does it expire?
Patent 11,666,573 protects ERZOFRI and is included in one NDA.
This patent has seven patent family members in six countries.
Drugs Protected by US Patent 11,666,573
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Luye Innomind Pharma | ERZOFRI | paliperidone palmitate | SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 216352-001 | Jul 26, 2024 | RX | Yes | Yes | 11,666,573 | ⤷ Subscribe | DOSING REGIMEN FOR THE TREATMENT OF SCHIZOPHRENIA IN ADULTS BY ADMINISTERING AN INITIAL DOSE OF PALIPERIDONE PALMITATE FOLLOWED BY MONTHLY DOSE(S) | ⤷ Subscribe | ||||
Luye Innomind Pharma | ERZOFRI | paliperidone palmitate | SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 216352-001 | Jul 26, 2024 | RX | Yes | Yes | 11,666,573 | ⤷ Subscribe | DOSING REGIMEN FOR THE TREATMENT OF SCHIZOAFFECTIVE DISORDER IN ADULTS AS MONOTHERAPY AND AS AN ADJUNCT TO MOOD STABILIZERS OR ANTIDEPRESSANTS BY ADMINISTERING AN INITIAL DOSE OF PALIPERIDONE PALMITATE FOLLOWED BY MONTHLY DOSE(S) | ⤷ Subscribe | ||||
Luye Innomind Pharma | ERZOFRI | paliperidone palmitate | SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 216352-002 | Jul 26, 2024 | RX | Yes | Yes | 11,666,573 | ⤷ Subscribe | DOSING REGIMEN FOR THE TREATMENT OF SCHIZOAFFECTIVE DISORDER IN ADULTS AS MONOTHERAPY AND AS AN ADJUNCT TO MOOD STABILIZERS OR ANTIDEPRESSANTS BY ADMINISTERING AN INITIAL DOSE OF PALIPERIDONE PALMITATE FOLLOWED BY MONTHLY DOSE(S) | ⤷ Subscribe | ||||
Luye Innomind Pharma | ERZOFRI | paliperidone palmitate | SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 216352-002 | Jul 26, 2024 | RX | Yes | Yes | 11,666,573 | ⤷ Subscribe | DOSING REGIMEN FOR THE TREATMENT OF SCHIZOPHRENIA IN ADULTS BY ADMINISTERING AN INITIAL DOSE OF PALIPERIDONE PALMITATE FOLLOWED BY MONTHLY DOSE(S) | ⤷ Subscribe | ||||
Luye Innomind Pharma | ERZOFRI | paliperidone palmitate | SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 216352-003 | Jul 26, 2024 | RX | Yes | Yes | 11,666,573 | ⤷ Subscribe | DOSING REGIMEN FOR THE TREATMENT OF SCHIZOAFFECTIVE DISORDER IN ADULTS AS MONOTHERAPY AND AS AN ADJUNCT TO MOOD STABILIZERS OR ANTIDEPRESSANTS BY ADMINISTERING AN INITIAL DOSE OF PALIPERIDONE PALMITATE FOLLOWED BY MONTHLY DOSE(S) | ⤷ Subscribe | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 11,666,573
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Australia | 2018354431 | ⤷ Subscribe | |||
Canada | 3077224 | ⤷ Subscribe | |||
European Patent Office | 3700531 | ⤷ Subscribe | |||
Japan | 2021501200 | ⤷ Subscribe | |||
Japan | 7337080 | ⤷ Subscribe | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |